Abstract
Iodine-131 (131I, radioiodine) has been used for over eight decades for the treatment of Graves’ disease, either as initial therapy or following failure of thionamides, as well as for the treatment of autonomous thyroid nodules. 131I treatment is simple to administer, effective, and relatively inexpensive. Recently, there has been some turmoil after a study published in JAMA Internal Medicine reported an increased risk of cancer from 131I treatment. The impact was of short duration however, as the paper received severe criticisms from many nuclear medicine physicians as well as from endocrinologists. Here we explain why that paper's conclusions are doubtful. We also review the major data on the topic of 131I therapy of hyperthyroidism and the risk of cancer.
Translated title of the contribution | Discussion on radioactive iodine treatment of hyperthyroidism and the risk of induced cancer |
---|---|
Original language | English |
Pages (from-to) | 287-289 |
Number of pages | 3 |
Journal | Medecine Nucleaire |
Volume | 44 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2020 |
Bibliographical note
Publisher Copyright:© 2020 Elsevier Masson SAS
Keywords
- Cancer
- Hyperthyroidism
- I
- Radioactive iodine
- Radioiodine therapy
- Secondary cancer
ASJC Scopus subject areas
- Biophysics
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging